139 related articles for article (PubMed ID: 16010161)
1. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
3. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
4. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients.
Robbins BL; Tran TT; Pinkerton FH; Akeb F; Guedj R; Grassi J; Lancaster D; Fridland A
Antimicrob Agents Chemother; 1998 Oct; 42(10):2656-60. PubMed ID: 9756772
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial.
Lam K; Kraft WK; Zhan T; Lam E
Clin Transl Sci; 2024 Mar; 17(3):e13721. PubMed ID: 38421210
[TBL] [Abstract][Full Text] [Related]
6. The anti-HIV drug abacavir stimulates β-catenin activity in osteoblast lineage cells.
Olali AZ; Wallace J; Gonzalez H; Carpenter KA; Patel N; Winchester LC; Podany AT; Venkatesh I; Narasipura SD; Al-Harthi L; Ross RD
JBMR Plus; 2024 May; 8(5):ziae037. PubMed ID: 38590756
[TBL] [Abstract][Full Text] [Related]
7. Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.
Solas C; Li YF; Xie MY; Sommadossi JP; Zhou XJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2989-95. PubMed ID: 9797238
[TBL] [Abstract][Full Text] [Related]
8. ProTide generated long-acting abacavir nanoformulations.
Lin Z; Gautam N; Alnouti Y; McMillan J; Bade AN; Gendelman HE; Edagwa B
Chem Commun (Camb); 2018 Jul; 54(60):8371-8374. PubMed ID: 29995046
[TBL] [Abstract][Full Text] [Related]
9. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Pruvost A; Théodoro F; Agrofoglio L; Negredo E; Bénech H
J Mass Spectrom; 2008 Feb; 43(2):224-33. PubMed ID: 17935070
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
[TBL] [Abstract][Full Text] [Related]
13. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
[TBL] [Abstract][Full Text] [Related]
15. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
[TBL] [Abstract][Full Text] [Related]
16. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Bazzoli C; Jullien V; Le Tiec C; Rey E; Mentré F; Taburet AM
Clin Pharmacokinet; 2010; 49(1):17-45. PubMed ID: 20000887
[TBL] [Abstract][Full Text] [Related]
17. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of lamivudine.
Johnson MA; Moore KH; Yuen GJ; Bye A; Pakes GE
Clin Pharmacokinet; 1999 Jan; 36(1):41-66. PubMed ID: 9989342
[TBL] [Abstract][Full Text] [Related]
19. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
20. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Ma B; Barth A; McHale CM; Lai MT
Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
